Ascensia Diabetes Care is launching the Eversense 365 continuous glucose monitoring system to people with diabetes in the U.S. Developed by Senseonics Holdings, Eversense 365 is the only CGM that provides one year of accurate monitoring with minimal disruptions, enabling confident decisions, long-term peace of mind, and enhanced quality of life with just one CGM. The device was cleared for use last month by the U.S. Food and Drug Administration for people with type 1 and type 2 diabetes aged 18 years and older.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SENS:
- Senseonics receives FDA clearance for Eversense 365 CGM system
- Senseonics announces FDA clearance for Eversense 365 CGM system
- Senseonics affirms FY24 revenue view of $22M-$24M, consensus $25.1M
- Senseonics reports Q2 EPS (3c), consensus (3c)
- SENS Earnings Report this Week: Is It a Buy, Ahead of Earnings?